Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Raised to $74.00 at HC Wainwright

Xenon Pharmaceuticals (NASDAQ:XENE) had its price objective upped by HC Wainwright from $53.00 to $74.00 in a research note issued to investors on Tuesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Robert W. Baird raised their price objective on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday. JPMorgan Chase & Co. boosted their target price on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Chardan Capital upgraded Xenon Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Wells Fargo & Company lifted their price target on Xenon Pharmaceuticals from $48.00 to $49.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $71.94.

Xenon Pharmaceuticals Price Performance

XENE stock opened at $60.61 on Tuesday. The firm has a market cap of $5.04 billion, a PE ratio of -13.90 and a beta of 0.91. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $63.95. The firm has a 50 day simple moving average of $42.95 and a 200 day simple moving average of $41.56.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same period in the previous year, the business posted ($0.84) EPS. As a group, sell-side analysts expect that Xenon Pharmaceuticals will post -3.1 earnings per share for the current year.

Insiders Place Their Bets

In other Xenon Pharmaceuticals news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $266,580. The trade was a 86.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

A number of hedge funds have recently modified their holdings of XENE. Neo Ivy Capital Management acquired a new stake in shares of Xenon Pharmaceuticals in the third quarter worth $2,001,000. JPMorgan Chase & Co. raised its position in Xenon Pharmaceuticals by 11.3% during the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after buying an additional 142,452 shares during the period. Marshall Wace LLP raised its position in Xenon Pharmaceuticals by 34.6% during the second quarter. Marshall Wace LLP now owns 1,020,254 shares of the biopharmaceutical company’s stock valued at $31,934,000 after buying an additional 262,109 shares during the period. American Century Companies Inc. purchased a new stake in Xenon Pharmaceuticals in the 2nd quarter worth about $21,280,000. Finally, Westfield Capital Management Co. LP lifted its stake in Xenon Pharmaceuticals by 4.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,206,066 shares of the biopharmaceutical company’s stock worth $48,424,000 after acquiring an additional 53,461 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals News Summary

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: Phase 3 X‑TOLE2 topline results show azetukalner produced a statistically significant reduction in focal‑onset seizure frequency, positioning the drug for an NDA submission targeted in Q3 2026 — a major clinical milestone that drove the earlier sharp rally. GlobeNewswire: X-TOLE2 Results Reuters: Trial Meets Main Goal
• Positive Sentiment: Multiple brokerages raised price targets and maintained bullish ratings (HC Wainwright, Deutsche Bank, Needham, Wells Fargo, Wedbush), reflecting upwardly revised sales and valuation assumptions after the Phase 3 readout. Benzinga: Analyst Upgrades
• Neutral Sentiment: Trading was temporarily halted ahead of the announcement, indicating the exchange processed material news that subsequently drove heavy intraday activity. (News pending/halt was lifted following the topline release.)
• Neutral Sentiment: Yesterday’s massive intraday rally — driven by the trial news — created rapid re‑rating and higher volatility; that squeeze can produce follow‑through profit‑taking and larger volume swings. 247WallSt: Big One‑Day Gain
• Negative Sentiment: Xenon announced a proposed underwritten public offering of $500M of common shares (with a 30‑day option for an additional $75M). Issuing new equity after a large run‑up creates dilution risk and puts selling pressure on the stock even though proceeds could fund commercialization and ongoing trials. GlobeNewswire: Offering MSN: Offering Coverage

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.